contrl group:The Placebo
Sponsors
The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Conditions
Non-small cell lung cancer
Early Phase 1
Efficacy and safety of topical Xiaozhenzhiyang in the treatment of epidermal growth factor receptor (EGFR) inhibitor-associated rash: a multiple center, randomized, double blinding, placebo-controlled trial
Active, not recruitingChiCTR2000029524
Start: 2022-03-01Updated: 2020-02-03
Efficacy and safety of topical Xiaozhenzhiyang in the treatment of epidermal growth factor receptor (EGFR) inhibitor-associated rash: a multiple center, randomized, double blinding, placebo-controlled tri
Active, not recruitingITMCTR2000002966
Start: 2022-03-01Updated: 2023-02-20